GLP Toxicology Study Costs in 2026

What does a GLP toxicology study cost in 2026?

Start with the three numbers that anchor every first-in-human budget. Published industry ranges for 2026 put a 28-day GLP repeat-dose study at $250K to $450K in rodents, $450K to $750K in dogs, and $650K to $1.1M in non-human primates, all US pricing. If your program needs two species (most small molecules do), the pivotal repeat-dose pair alone is a seven-figure decision.

The rest of the IND tox package stacks on top. Typical quotes we see referenced put the safety pharmacology core battery (hERG patch clamp, cardiovascular telemetry, functional observational battery, respiratory plethysmography) at $270K to $530K, and the genotoxicity battery at $75K to $135K. Earlier, cheaper work feeds it all: single-dose MTD studies in rodents quote at $40K to $80K non-GLP, and a dose-range-finding pair (rodent plus non-rodent) at roughly $80K to $150K.

Put together, a full small-molecule IND-enabling program typically lands between $1.5M and $3.5M. That spread is not vendor noise. It reflects real design choices: species, study durations, group sizes, recovery arms, and where in the world the work runs. The sections below unpack each lever so you can read a CRO quote the way a tox program manager does.

What actually drives the price of a GLP tox study?

Five levers set most of the price. Species is the largest single factor. The others compound, and they compound fastest on non-rodent studies, where every animal added to the design drags acquisition, housing, dosing labor, clinical pathology, and histopathology along behind it.

Here is where the money actually goes:

• Species and sourcing: rodents cost little per animal but need large groups; purpose-bred beagles and NHPs cost orders of magnitude more each, and NHP acquisition prices spiked sharply after 2020 and never fully retraced.
• Duration: a 90-day study is not simply three times a 28-day study, but longer in-life means more per diems, more TK bleeds, more clinical pathology timepoints, and a much bigger histopathology read.
• Group sizes and recovery arms: a standard rodent design runs about 10 per sex per group across four groups, plus TK satellites. Every recovery cohort adds animals, extra weeks of housing, and a second necropsy and histopathology round.
• Toxicokinetic sampling: satellite groups in rodents, serial bleeds in large animals, hundreds of samples through a validated bioanalytical method. TK is often quoted separately, and it is not small.
• GLP QA overhead: 21 CFR Part 58 compliance means protocol review, in-life inspections, data audits, and QA sign-off on the report. That is real headcount billed into the study, and it is the core of the non-GLP vs GLP cost gap.

None of these levers are padding, but each one is negotiable at the design stage. That is why the same molecule can come back as a $300K quote from one facility and a $500K quote from another under what looks like the same study title.

How do rodent, dog, and NHP study economics compare?

Rodent studies are the workhorse: $250K to $450K for a 28-day GLP design, per published ranges. The animals are cheap; the design is big. You are running main-study groups plus toxicokinetic satellites, and the histopathology read covers forty-plus tissues across a hundred or more animals. Labor and pathology dominate the invoice, not animal cost.

Dog studies flip the math. A 28-day GLP dog study runs $450K to $750K with far fewer animals, typically 3 to 4 per sex per group, because each purpose-bred beagle carries meaningful acquisition cost, individual housing, and per-animal dosing and observation labor. NHP studies push further still, at $650K to $1.1M, and animal acquisition is often the single biggest line item: NHP supply tightened dramatically after 2020 and pricing remains elevated at every major CRO.

The uncomfortable truth for budgeting: species selection is a science decision you cannot buy your way out of. If your metabolite profile or target biology makes NHP the only pharmacologically relevant non-rodent species (common for biologics), the budget follows the science. Spend early on DMPK and ADME characterization so the species call is defensible before you book a seven-figure slot, not after.

What does a CRO quote include, and what gets passed through?

A typical GLP tox quote covers protocol development, in-life conduct (dosing, clinical observations, body weights, food consumption), clinical pathology, ophthalmology, necropsy and organ weights, histopathology, statistical analysis, and the audited report. That is the headline number in the bid grid.

The pass-throughs are where identical-looking quotes diverge. Watch for these billed at cost plus handling, or excluded entirely:

• Animal acquisition, especially NHPs, sometimes quoted only as an estimate subject to market pricing at study start
• Bioanalytical method development, validation, or transfer for TK sample analysis
• Toxicokinetic analysis and reporting when subcontracted to a separate group
• Dose formulation preparation and analytical verification of dosing solutions
• Test article shipping, storage, characterization, and stability support
• Archiving fees and long-term sample retention

Ask every bidder for the same line-item structure before you compare anything. A $350K headline with $150K of pass-throughs is not cheaper than a $450K all-in quote, and the difference usually surfaces three months into the study, when it is too late to rebid.

Why do quotes for the same study vary 2-3x between CROs?

Send one protocol synopsis to five CROs and the returns can legitimately span 2-3x. The first reason is capacity pricing. A facility with open slots next quarter prices to fill them; a facility booked nine months out prices to manage demand. Same study, different market.

The second reason is design assumptions. One CRO quotes the lean ICH M3(R2) minimum: standard group sizes, recovery on control and high dose only, sparse TK sampling. Another quotes belt and suspenders: extra recovery arms, added immunophenotyping, a full ophthalmology and ECG schedule. Both are defensible. They are not the same study, even under the same title.

Then geography and tier. EU and Asian GLP facilities typically quote 20 to 40% below comparable US pricing, and mid-size CROs often undercut the multinationals on identical designs. None of this maps cleanly to quality: GLP is GLP, and FDA accepts OECD-compliant studies from member countries. What it does mean is that comparing headline numbers without normalizing design, deliverables, and pass-through treatment is how early-stage programs overpay.

When is non-GLP acceptable, and when is GLP mandatory?

Everything before the pivotal package can and should run non-GLP: single-dose and MTD work ($40K to $80K in rodents), dose-range-finding studies ($80K to $150K for the rodent plus non-rodent pair), and any screening or candidate-selection tox. Regulators do not expect GLP here. Paying GLP overhead on studies whose only job is to pick doses is wasted budget.

The line is the IND. Safety studies that support first-in-human dosing (the definitive repeat-dose studies, the safety pharmacology core battery, the genotoxicity battery) must comply with GLP under 21 CFR Part 58 for FDA, or OECD GLP principles for EU regulators. File pivotal work that was run non-GLP and you are writing a compliance justification at best, repeating the study at worst.

The false economy to avoid: skipping the DRF to save $100K and going straight to GLP. If the high dose in your pivotal study is wrong (too toxic and you lose animals, too clean and you have no margin characterization), the do-over costs the full study price plus four to six months. The cheap non-GLP work exists to protect the expensive GLP work.

How long does a GLP tox study take from slot to draft report?

Budget the calendar as carefully as the dollars. GLP slots at reputable facilities commonly book several months out, and NHP studies add further lead time for animal sourcing and quarantine. Reserve slots when your DRF data is nearly in hand, not after the final report lands.

The in-life phase is the short part: 28 days of dosing plus an optional 14-day recovery. The long pole is everything after necropsy. Histopathology slide preparation, the pathologist's read, peer review, QA audit of the data and draft, and report assembly typically take two to four months after the last animal comes down.

End to end, plan roughly six to nine months from slot reservation to audited draft report for a 28-day GLP study, longer for NHP. At the program level, a full IND-enabling package (two-species repeat-dose, safety pharmacology, genotox, plus the bioanalytical validation feeding all of it) typically runs 12 to 18 months. Teams that treat the tox timeline as the critical path to IND rarely regret it.

How do you cut tox costs without cutting quality?

There is real money to save in study design, and none of it requires worse science. The savings come from stripping redundancy and matching the design to what regulators actually expect, rather than gold-plating.

What not to cut: pathology peer review, TK sampling adequacy, or GLP status on pivotal work. Those savings are small and the downside is a repeated study.

• Combine endpoints. For biologics, cardiovascular and respiratory safety pharmacology endpoints can often fold into the repeat-dose NHP study instead of standing alone, per ICH S6(R1). That can save a six-figure standalone telemetry study.
• Right-size groups and recovery arms. Recovery cohorts on control and high dose only, unless findings force more. Every extra arm is animals, housing, and a second histopathology round.
• Validate bioanalytical methods once. Develop and validate the TK method at one site and transfer it, rather than paying for parallel validations at every facility touching samples.
• Consider EU and Asian sites for the pivotal package. A 20 to 40% discount on a $2M program is $400K to $800K, and OECD GLP data is accepted by FDA.
• Sequence properly. DRF before GLP, genotox early (an Ames positive changes everything), and lock formulation before the pivotal studies so you are not paying for bridging work.
• Bid competitively. Three to five quotes on an identical design synopsis is the single highest-ROI hour a program lead spends.

How do you get real numbers for your program?

Published ranges get you to a defensible board-level budget, but your actual number depends on your molecule, species call, formulation, and timing. The only way to know is to put a real design synopsis in front of multiple qualified GLP facilities and compare structured bids.

That is what BioBridgeX is built for. Post your study package once, then Compare quotes from vetted GLP toxicology CROs side by side on normalized line items. The marketplace is neutral and free for buyers: suppliers pay a 2% success fee only when they are awarded the work and paid, and you contract and pay your CRO directly. If you want a program-level starting point first, the free IND Budget Calculator turns the ranges on this page into a line-item budget for your program.

Either way, go into CRO conversations with ranges in hand. The teams that know a 28-day rodent study should land between $250K and $450K negotiate very differently from the teams seeing their first tox quote cold.